UNCY Stock: Dilution, SEC Filings & News

UNCY Unicycive Therapeutics, Inc.

Price$3.69

Company About

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

NASDAQ Capital Market

Vol Avg.

942.44 K

Inst Own

1.700%

Float & OS

27.56 M / 28.23 M

Cash/Shr

$1.8

Market Cap & Ev

100.21 M / 62.67 M

Short Interest

17.7%

Borrow Rate

0.8627%

Days to Cover

4.82

Overall Offering Risk

Warrant Exercise Risk

Research Report

Customize research

Recent Articles (8)

View All

Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

Globe Newswire

Nov 4, 2026, 7:05 AM

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Business Wire

Nov 2, 2026, 12:35 PM

Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY

Globe Newswire

Nov 2, 2026, 10:31 AM

UNCY UPCOMING DEADLINE: Levi & Korsinsky Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm

ACCESS Newswire

Oct 30, 2026, 10:15 AM

Kaplan Fox Alerts Investors: Lead Plaintiff Deadline for Unicycive Therapeutics, Inc. (UNCY) is November 2, 2026

Newsfile

Oct 29, 2026, 6:30 PM

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

PRNewswire

Oct 29, 2026, 10:09 AM

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

PRNewswire

Oct 28, 2026, 3:38 PM

UNCY Deadline: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights

Business Wire

Oct 27, 2026, 4:30 PM

Recent Filings

View All

Type	Title	Date Released
4	Manning Meredith (Reporting)	Oct 29, 2026, 4:30 PM
3	Manning Meredith (Reporting)	Oct 1, 2026, 4:30 PM
8-K	Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate	Sep 29, 2026, 7:46 AM
8-K	Unicycive Therapeutics Faces Securities Class Action Lawsuit	Sep 28, 2026, 4:31 PM
SCHEDULE 13G/A	Nantahala Capital Management, LLC (Filed by)	Aug 14, 2026, 4:37 PM
SCHEDULE 13G/A	Vivo Opportunity Fund Holdings, L.P. (Filed by)	Aug 14, 2026, 4:15 PM
8-K	Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Business Update	Aug 12, 2026, 8:04 AM
10-Q	Form 10-Q	Aug 12, 2026, 6:30 AM
SCHEDULE 13G	BlackRock, Inc. (Filed by)	Jul 30, 2026, 11:18 AM
4/A	Kenkare-Mitra Sara (Reporting)	Jul 28, 2026, 4:15 PM
4/A	Laumas Sandeep (Reporting)	Jul 28, 2026, 4:15 PM
SCHEDULE 13G/A	INTEGRATED CORE STRATEGIES (US) LLC (Filed by)	Jul 8, 2026, 5:51 PM

Earnings

Nov

Q4 2026 Earnings reportUpcoming

Aug

Q3 2026 Earnings report

-0.06%beat

May

Q2 2026 Earnings report

-0.54%beat

Mar

Q1 2026 Earnings report

-0.82%missed

Nov

Q4 2025 Earnings report

-0.33%beat

Aug

Q3 2025 Earnings report

-0.52%beat

Related Healthcare stocks

All tickers

Unicycive Therapeutics, Inc. UNCY

Related Healthcare stocks

Related Healthcare stocks